HIFU SONABLATE 500 RECEIVES TGA MARKET APPROVAL IN AUSTRALIA
THS International, Inc, the exclusive distributor for the advanced HIFU Sonablate(R) 500 in Asia and Australia, announces that the Therapeutic Goods Administration (TGA) in Australia has given full market approval to the Sonablate(R) 500, which has been used for the minimally invasive treatment of prostate cancer. The Sonablate(R) 500 uses advanced High Intensity Focused Ultrasound (HIFU) energy, which is sharply focused and destroys targeted prostate tissue without affecting the intervening tissue. The advanced Sonablate(R) technology has been used to treat over 4,000 men for prostate cancer and benign prostate hyperplasia around the world.
Medical News Today (http://www.medicalnewstoday.com/medicalnews.php?newsid=29295)